Tvardi Therapeutics (TVRD)
Market Price (10/2/2026): $1.25 | Market Cap: $11.7 MilSector: Health Care | Industry: Biotechnology
Tvardi Therapeutics (TVRD)
Market Price (10/2/2026): $1.25Market Cap: $11.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Key risksTVRD key risks include [1] the recent Phase 2 clinical trial failure of its lead candidate, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Key risksTVRD key risks include [1] the recent Phase 2 clinical trial failure of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Tvardi Therapeutics (TVRD) stock has lost about 35% since 6/30/2026 because of the following key factors:
1. Deteriorating Financial Performance in Fiscal Q2 2026.
Tvardi Therapeutics reported a net loss of $6.5 million for fiscal Q2 2026, which ended on June 30, 2026. This represented a significant widening compared to the net income of $4.2 million reported in fiscal Q2 2025. Additionally, the company's cash, cash equivalents, and short-term investments decreased substantially to $15.8 million by June 30, 2026, down from $30.8 million at the close of fiscal year 2025, indicating continued cash burn. While the company extended its cash runway guidance into fiscal Q3 2027, these underlying negative financial results contributed to sustained downward pressure on the stock.
2. Negative Market Reaction to Preclinical Data for TTI-101 in Ulcerative Colitis.
On September 24, 2026, Tvardi Therapeutics announced the publication of new preclinical data for its STAT3 inhibitors in ulcerative colitis (UC). Despite the company indicating that the data supported further potential, the market reacted unfavorably, leading to a significant stock price drop of Show more
Tvardi Therapeutics (TVRD) stock has lost about 35% since 6/30/2026 because of the following key factors:
1. Deteriorating Financial Performance in Fiscal Q2 2026.
Tvardi Therapeutics reported a net loss of $6.5 million for fiscal Q2 2026, which ended on June 30, 2026. This represented a significant widening compared to the net income of $4.2 million reported in fiscal Q2 2025. Additionally, the company's cash, cash equivalents, and short-term investments decreased substantially to $15.8 million by June 30, 2026, down from $30.8 million at the close of fiscal year 2025, indicating continued cash burn. While the company extended its cash runway guidance into fiscal Q3 2027, these underlying negative financial results contributed to sustained downward pressure on the stock.
2. Negative Market Reaction to Preclinical Data for TTI-101 in Ulcerative Colitis.
On September 24, 2026, Tvardi Therapeutics announced the publication of new preclinical data for its STAT3 inhibitors in ulcerative colitis (UC). Despite the company indicating that the data supported further potential, the market reacted unfavorably, leading to a significant stock price drop of -19.70% on that day. This suggests investors may have found the preclinical results less impactful than expected for a clinical-stage company, or the news raised concerns regarding the extensive capital and time required for advancing these programs into later-stage clinical trials.
3. Broader Investor Caution in the Small-Cap Biotechnology Sector.
The persistent decline in Tvardi Therapeutics' stock, which has seen a 96.5% loss over the past 12 months (as of September 25, 2026) and a 70.2% decrease since the start of fiscal year 2026, underscores a challenging investment climate for small-cap clinical-stage biopharmaceutical companies. With a market capitalization of approximately $16.67 million as of September 30, 2026, and a continued lack of profitability, investor sentiment toward higher-risk biotech ventures with prolonged commercialization timelines likely diminished, contributing to an overall bearish trend for the stock.
Show less
Stock Movement Drivers
Fundamental Drivers
The -34.7% change in TVRD stock from 6/30/2026 to 10/1/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302026 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.90 | 1.24 | -34.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 9 | 9 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2026 to 10/1/2026| Return | Correlation | |
|---|---|---|
| TVRD | -34.7% | |
| Market (SPY) | 2.3% | -7.1% |
| Sector (XLV) | 4.8% | 5.5% |
Fundamental Drivers
The -61.0% change in TVRD stock from 3/31/2026 to 10/1/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.18 | 1.24 | -61.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | |
| P/S Multiple | 3.8 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 3 | 9 | -72.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 10/1/2026| Return | Correlation | |
|---|---|---|
| TVRD | -61.0% | |
| Market (SPY) | 17.8% | 12.4% |
| Sector (XLV) | 13.9% | -1.5% |
Fundamental Drivers
The -96.8% change in TVRD stock from 9/30/2025 to 10/1/2026 was primarily driven by a -72.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.97 | 1.24 | -96.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 3 | 9 | -72.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 10/1/2026| Return | Correlation | |
|---|---|---|
| TVRD | -96.8% | |
| Market (SPY) | 15.6% | 4.5% |
| Sector (XLV) | 21.0% | 1.9% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2023 to 10/1/2026| Return | Correlation | |
|---|---|---|
| TVRD | ||
| Market (SPY) | 84.9% | 6.7% |
| Sector (XLV) | 35.2% | 4.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TVRD Return | - | - | - | - | -76% | -70% | -93% |
| Peers Return | -7% | 32% | 41% | -1% | 13% | 0% | 93% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| TVRD Win Rate | - | - | - | - | 67% | 33% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 83% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| TVRD Max Drawdown | - | - | - | - | - | -79% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/1/2026 (YTD)
How Low Can It Go
TVRD has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
TVRD has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Tvardi Therapeutics (TVRD)
Cara Therapeutics, Inc. (symbol: TVRD) is an early commercial-stage biopharmaceutical company focused on developing and marketing novel treatments for pruritus (itching) and pain. The company's therapeutic approach involves selectively targeting kappa opioid receptors, with product candidates designed to act on the body's peripheral nervous system and immune cells. While its primary focus is the United States, Cara Therapeutics also has licensing agreements for its compounds in Japan and South Korea, indicating a broader potential market for its specialized treatments.
The company's lead commercial product is KORSUVA (difelikefalin) injection, which is approved for treating moderate-to-severe pruritus in adult patients with chronic kidney disease (CKD) who are undergoing hemodialysis. Beyond its approved injection, Cara Therapeutics is also advancing an oral formulation of difelikefalin, Oral KORSUVA, through Phase II clinical trials. This oral candidate is being investigated for a range of pruritic conditions including atopic dermatitis, non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus, pruritus linked to chronic liver disease (CLD) primary biliary cholangitis (PBC), and notalgia paresthetica.
Cara Therapeutics serves a patient population suffering from severe chronic pruritus, particularly those with kidney disease requiring hemodialysis. Its ongoing clinical trials for Oral KORSUVA aim to expand its reach to patients experiencing pruritus related to various other conditions, including different stages of kidney disease, liver disease, and specific dermatological issues. Through strategic licensing, the company also addresses potential markets for acute pain and uremic pruritus in Asian territories, broadening its global impact on difficult-to-treat conditions.
```AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Imran Alibhai, Ph.D., Chief Executive Officer
Prior to becoming CEO of Tvardi, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical-stage biotech company focused on oncolytic viruses for cancer. During his tenure at DNAtrix, the company secured multiple financing rounds, initiated a Phase 2 immuno-oncology collaboration with Merck, and advanced a next-generation armed virus into the clinic. He previously worked as an investment banker in PJ Solomon's Healthcare Advisory Group, concentrating on M&A transactions in science-based markets. Dr. Alibhai also held roles as Senior Director at Alexandria Venture Investments, where he managed investments in emerging healthcare companies, and directed investments for MPM Capital's BioEquities hedge fund. He began his career in early-stage venture capital at the Accelerator Corp., gaining experience in company formation and management.
Dan Conn, J.D., M.B.A., Chief Financial Officer
Mr. Conn brings a comprehensive background in corporate law, finance, and business management. He started his career as an M&A and securities lawyer before transitioning to investment banking. As an investment banker, he served as an Executive Director at Morgan Stanley and a Director at PJ Solomon, where he focused on M&A, restructuring, and financing transactions across the life sciences and other sectors. Mr. Conn also worked on the buy side, investing in various industries, including life sciences, as a Vice President and Portfolio Manager at D.E. Shaw & Co and later as a Senior Vice President and Portfolio Manager at Brookfield Asset Management. His recent focus has been on operational aspects, directing the development and monetization of intellectual property rights.
John Kauh, M.D., Chief Medical Officer
Dr. Kauh is a board-certified medical oncologist with demonstrated leadership in both early and late-phase drug development. His experience includes guiding US and EU regulatory submissions for drug approval.
Joseph Chen, Ph.D., Vice President, CMC
Dr. Chen possesses 25 years of experience in the Chemistry, Manufacturing, and Controls (CMC) development of drug substances and products. He has extensive expertise in both technical leadership and management oversight for CMC development and manufacturing, both in-house and with Contract Manufacturing Organizations (CMOs). Prior to joining Tvardi, he held positions of increasing responsibility at Boehringer Ingelheim, Tanox, Johnson-Johnson, and Lexicon Pharmaceuticals, leading CMC development for numerous pharmaceutical and biological products.
Stephen O'Brien, CPA, VP, Finance and Corporate Controller
Mr. O'Brien has over 20 years of experience in accounting and financial reporting within the life sciences industry, working with both private and public companies. He was responsible for financial reporting at Eyetech Pharmaceuticals and 3-Dimensional Pharmaceuticals, where he played a role in their IPO processes and managed ongoing public reporting after their listings.
AI Analysis | Feedback
Key Risks to Tvardi Therapeutics
- Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Tvardi Therapeutics' success is heavily dependent on the successful outcome of its ongoing clinical trials and subsequent regulatory approvals for its product candidates. The company's lead product candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). A significant concern is the reported failure of the lead lung disease candidate to show clinical benefit in preliminary Phase 2 REVERT trial data, which led to a significant stock decline. Negative results from ongoing or future clinical trials, or the inability to obtain regulatory approval, would severely impact the company's viability and stock performance.
- Financial Sustainability and Funding Risk: Tvardi Therapeutics exhibits signs of financial strain, having reported a deeply negative net margin of -678.79% and a return on equity of -565.83%. These metrics raise serious concerns about the company's ability to sustain operations long enough to achieve clinical milestones and commercialize its products. The company went public in April 2025 through a merger with Cara Therapeutics, a move that provided access to critical funding required to advance its pipeline programs. However, continued heavy investment in clinical development without a clear path to profitability or sustained funding could jeopardize its long-term operations.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Peer Outperformance in Biotechnology
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 4 | 23.7% | 92.7% | 266.5% | CAH 409% · MCK 360% · COR 173% |
| Biotechnology ← | 28 | 40.4% | 82.9% | 65.4% | ADMA 734% · PTGX 675% · KRYS 504% |
| Health Care Facilities | 10 | -0.7% | 57.9% | 53.8% | THC 269% · NHC 262% · ENSG 127% |
| Pharmaceuticals | 26 | 11.8% | 55.4% | 48.1% | INDV 1116% · LQDA 918% · CORT 475% |
| Health Care Services | 20 | 15.9% | 34.3% | 3.3% | HIMS 301% · RDNT 133% · DGX 78% |
| Managed Health Care | 6 | 12.3% | -16.0% | 1.8% | HQY 34% · ELV 9% · UNH 2% |
| Health Care Equipment | 33 | -4.2% | 1.7% | -13.1% | UFPT 377% · GKOS 236% · TMDX 141% |
| Life Sciences Tools & Services | 13 | 21.0% | 34.5% | -19.1% | MEDP 206% · WAT 20% · TMO 16% |
| Health Care Supplies | 12 | 22.0% | -8.4% | -38.9% | LNTH 285% · HAE 45% · MMSI 19% |
| Health Care Technology | 5 | -3.9% | 34.5% | -64.1% | HSTM 6% · VEEV -2% · DOCS -64% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Tvardi Therapeutics Earnings Notes | 12/16/2025 | |
| Can Tvardi Therapeutics Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 508.80 |
| Mkt Cap | 129.1 |
| Rev LTM | 12,587 |
| Op Inc LTM | 4,777 |
| FCF LTM | 3,796 |
| FCF 3Y Avg | 1,957 |
| CFO LTM | 4,293 |
| CFO 3Y Avg | 2,398 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.8% |
| Rev Chg Q | 12.5% |
| QoQ Delta Rev Chg LTM | 3.0% |
| Op Inc Chg LTM | 2,497.9% |
| Op Inc Chg 3Y Avg | 792.2% |
| Op Mgn LTM | 37.9% |
| Op Mgn 3Y Avg | 23.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 34.1% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | 30.2% |
| FCF/Rev 3Y Avg | 15.7% |
Segment Financials
Revenue by Segment| $ Mil | 2023 | 2022 |
|---|---|---|
| Discovery and development of novel orally bioavailable, small molecule therapies across a broad | 0 | 0 |
| Total | 0 | 0 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Discovery and development of novel orally bioavailable, small molecule therapies across a broad | -18 | -29 |
| Total | -18 | -29 |
| $ Mil | 2023 | 2022 |
|---|---|---|
| Discovery and development of novel orally bioavailable, small molecule therapies across a broad | 27 | 45 |
| Total | 27 | 45 |
Price Behavior
| Market Price | $1.24 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/31/2014 | |
| Distance from 52W High | -97.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.81 | $13.84 |
| DMA Trend | down | down |
| Distance from DMA | -31.6% | -91.0% |
| 3M | 1YR | |
| Volatility | 195.1% | 146.7% |
| Downside Capture | 8.84 | 174.13 |
| Upside Capture | -252.42 | -252.00 |
| Correlation (SPY) | -7.0% | 4.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.25 | 1.41 | -1.24 | 1.59 | 0.53 | 0.26 |
| Up Beta | -16.56 | -2.96 | -1.18 | 3.38 | 0.19 | -0.22 |
| Down Beta | -4.27 | -3.07 | 3.04 | 3.60 | 2.52 | 0.96 |
| Up Capture | 346% | 150% | -185% | -30% | -65% | -5% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 7 | 16 | 24 | 49 | 97 | 158 |
| Down Capture | 686% | 533% | -32% | 199% | 140% | 78% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 15 | 24 | 37 | 73 | 142 | 193 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TVRD | |
|---|---|---|---|---|
| TVRD | -96.9% | 146.5% | -1.26 | - |
| Sector ETF (XLV) | 21.0% | 16.0% | 1.00 | 1.9% |
| Equity (SPY) | 15.7% | 13.0% | 0.85 | 4.5% |
| Gold (GLD) | 7.7% | 29.6% | 0.25 | -7.5% |
| Commodities (DBC) | 43.7% | 20.8% | 1.64 | -3.3% |
| Real Estate (VNQ) | 1.2% | 13.6% | -0.16 | -1.5% |
| Bitcoin (BTCUSD) | -27.0% | 44.5% | -0.58 | 1.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TVRD | |
|---|---|---|---|---|
| TVRD | -41.7% | 133.7% | -0.47 | - |
| Sector ETF (XLV) | 6.3% | 15.2% | 0.23 | 4.5% |
| Equity (SPY) | 13.0% | 17.2% | 0.57 | 6.8% |
| Gold (GLD) | 18.6% | 18.9% | 0.80 | -7.5% |
| Commodities (DBC) | 10.3% | 19.6% | 0.40 | -5.1% |
| Real Estate (VNQ) | 0.4% | 18.9% | -0.08 | 1.9% |
| Bitcoin (BTCUSD) | 13.2% | 52.3% | 0.43 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TVRD | |
|---|---|---|---|---|
| TVRD | -23.6% | 133.7% | -0.47 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.51 | 4.5% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 6.8% |
| Gold (GLD) | 11.6% | 16.4% | 0.58 | -7.5% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | -5.1% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.17 | 1.9% |
| Bitcoin (BTCUSD) | 63.9% | 66.2% | 1.04 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | 7.3% | 3.4% | 3.4% |
| 5/8/2026 | -0.7% | -5.9% | -32.3% |
| 11/13/2025 | -1.9% | -7.1% | 2.2% |
| 8/14/2025 | 0.9% | 12.0% | 41.9% |
| 5/13/2025 | -0.7% | 4.5% | -1.6% |
| SUMMARY STATS | |||
| # Positive | 2 | 3 | 3 |
| # Negative | 3 | 2 | 2 |
| Median Positive | 4.1% | 4.5% | 3.4% |
| Median Negative | -0.7% | -6.5% | -17.0% |
| Max Positive | 7.3% | 12.0% | 41.9% |
| Max Negative | -1.9% | -7.1% | -32.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | 7.3% | 3.4% | 3.4% |
| 5/8/2026 | -0.7% | -5.9% | -32.3% |
| 11/13/2025 | -1.9% | -7.1% | 2.2% |
| 8/14/2025 | 0.9% | 12.0% | 41.9% |
| 5/13/2025 | -0.7% | 4.5% | -1.6% |
| SUMMARY STATS | |||
| # Positive | 2 | 3 | 3 |
| # Negative | 3 | 2 | 2 |
| Median Positive | 4.1% | 4.5% | 3.4% |
| Median Negative | -0.7% | -6.5% | -17.0% |
| Max Positive | 7.3% | 12.0% | 41.9% |
| Max Negative | -1.9% | -7.1% | -32.3% |
Recent Forward Guidance
Updated 10/1/2026Latest: Q2 2026 Earnings Reported 8/14/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 TTI-101 Phase 1b/2 HCC topline data | Reported | |||||||
| 2027 Initiation of clinical trial of TTI-109 in UC | Reported | |||||||
Prior: Q1 2026 Earnings Reported 5/8/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Cash Runway | Reported | Affirmed | Guidance: 0 for Q4 2026 | |||||
Q3 2025 Earnings Reported 11/13/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Cash Runway | Reported | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.